US 12,408,673 B2
Paenibacillus strains and methods for their use
Jeremy Beau, Woodland, CA (US); Andreas Goertz, Dormagen (DE); Adam Newman, Sacramento, CA (US); Patrick Schwientek, Davis, CA (US); Colleen S. Taylor, Folsom, CA (US); Donglan Tian, Davis, CA (US); and Bjorn A. Traag, Walnut Creek, CA (US)
Assigned to Bayer CropScience LP, St. Louis, MO (US)
Appl. No. 17/435,848
Filed by Bayer CropScience LP, St. Louis, MO (US)
PCT Filed Mar. 5, 2020, PCT No. PCT/US2020/021125
§ 371(c)(1), (2) Date Sep. 2, 2021,
PCT Pub. No. WO2020/181053, PCT Pub. Date Sep. 10, 2020.
Claims priority of provisional application 62/815,069, filed on Mar. 7, 2019.
Prior Publication US 2022/0151242 A1, May 19, 2022
Int. Cl. A01N 63/25 (2020.01); C12N 1/20 (2006.01); C12R 1/07 (2006.01)
CPC A01N 63/25 (2020.01) [C12N 1/205 (2021.05); C12R 2001/07 (2021.05)] 18 Claims
 
1. A composition comprising a preservative and a biologically pure culture of a Paenibacillus sp. strain or a cell-free preparation thereof comprising a fusaricidin and a tridecaptin;
wherein the Paenibacillus sp. strain comprises a fusaricidin synthetase gene of fusA encoded by a DNA sequence exhibiting at least 90.5% sequence identity to SEQ ID NO: 3; and
the Paenibacillus sp. strain comprises a nonribosomal peptide synthetase (NRPS) gene of triE encoded by a DNA sequence exhibiting at least 90.0% sequence identity to SEQ ID NO: 7, wherein the culture comprises at least 1×104 colony forming units (CFU) of the strain per mL and wherein the Paenibacillus sp. strain is Paenibacillus sp. strain NRRL B-50374, Paenibacillus sp. strain NRRL B-67721, Paenibacillus sp. strain NRRL B-67723, Paenibacillus sp. strain NRRL B-67724, or a fungicidal mutant strain thereof.